Abnormal Sphingolipid World in Inflammation Specific for Lysosomal Storage Diseases and Skin Disorders

• Published in: International journal of molecular sciences Vol. 19; no. 1; p. 247
• Main Authors: Moskot, Marta, Bocheńska, Katarzyna, Jakóbkiewicz-Banecka, Joanna, Banecki, Bogdan, Gabig-Cimińska, Magdalena
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 15.01.2018; MDPI
• Subjects: Animals; Atopic dermatitis; Dermatitis; Disease Susceptibility; Drug therapy; Eczema; Flavonoids - pharmacology; Flavonoids - therapeutic use; Humans; Inflammatory diseases; Lipid Metabolism - drug effects; Lysosomal storage diseases; Lysosomal Storage Diseases - etiology; Lysosomal Storage Diseases - metabolism; Lysosomal Storage Diseases - therapy; Metabolic disorders; Metabolic pathways; Metabolic Syndrome - etiology; Metabolic Syndrome - metabolism; Metabolism; Pathogenesis; Pharmacology; Psoriasis; Review; Signal Transduction; Skin diseases; Skin Diseases - etiology; Skin Diseases - metabolism; Skin Diseases - therapy; skin disorders; sphingolipid metabolism alterations; Sphingolipids; Sphingolipids - metabolism; treatments; workable therapies; workable therapies; inflammatory diseases; lysosomal storage diseases; sphingolipid metabolism alterations; treatments; skin disorders
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms19010247

Research in recent years has shown that sphingolipids are essential signalling molecules for the proper biological and structural functioning of cells. Long-term studies on the metabolism of sphingolipids have provided evidence for their role in the pathogenesis of a number of diseases. As many inflammatory diseases, such as lysosomal storage disorders and some dermatologic diseases, including psoriasis, atopic dermatitis and ichthyoses, are associated with the altered composition and metabolism of sphingolipids, more studies precisely determining the responsibilities of these compounds for disease states are required to develop novel pharmacological treatment opportunities. It is worth emphasizing that knowledge from the study of inflammatory metabolic diseases and especially the possibility of their treatment may lead to insight into related metabolic pathways, including those involved in the formation of the epidermal barrier and providing new approaches towards workable therapies.